肥厚型心肌病相关基因的重新评估:ClinGen遗传性心血管疾病基因 curation 专家组的再评价
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is an inherited cardiac condition affecting ∼1 in 500 and exhibits marked genetic heterogeneity. Previously published in 2019, 57 HCM-associated genes were curated providing the first systematic evaluation of gene-disease validity.…
要点
- 17个(55%)再评估基因分类改变,9个(29%)降级为 disputed。
- TNNC1 升级为第9个 definitive 关联的肌节基因。
- 新评估基因中 FHOD3 为 definitive,RPS6KB1 和 RBM20 为 limited。
核心结论
- 报告29个基因对HCM或孤立性左心室肥厚具有 definitive、strong 或 moderate 证据。
研究设计与样本
- 采用ClinGen系统化基因 curation 框架,由HCVD GCEP(29名成员,来自6国21家机构)每两周会议评审。
主要发现
- 再评估基因中17个(55%)分类改变:1个 limited 和4个 disputed(来自无已知疾病关联),9个 disputed(来自 limited),3个 definitive(来自 moderate)。
- 3个(10%)基因具有临床相关升级,包括TNNC1成为第9个 definitive HCM 关联的肌节基因。
- 2个基因因新证据被 curated 为多种遗传模式:TRIM63(常染色体显性 disputed,常染色体隐性 moderate);ALPK3(常染色体显性 strong,隐性 definitive)。
- CSRP3 被 curated 为半显性遗传模式(definitive)。
- 9个(29%)基因降级为 disputed,进一步不建议临床报告这些基因的变异。
临床怎么用
- 临床报告HCM基因变异时应优先参考具有 definitive、strong 或 moderate 证据的29个基因。
- 对降级为 disputed 的9个基因,应避免常规临床报告其变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is an inherited cardiac condition affecting ∼1 in 500 and exhibits marked genetic heterogeneity. Previously published in 2019, 57 HCM-associated genes were curated providing the first systematic evaluation of gene-disease validity. OBJECTIVES: The authors report work by the Clinical Genome Resource Hereditary Cardiovascular Disease (HCVD) Gene Curation Expert Panel (GCEP) to reappraise the clinical validity of previously curated and new putative HCM genes. METHODS: The Clinical Genome Resource systematic gene curation framework was used to reclassify the gene-disease relationships for HCM and related syndromic entities involving left ventricular hypertrophy. Genes previously curated were included if their classification was not definitive, and if the time since curation was >2 to 3 years. New genes with literature assertions for HCM were included for initial evaluation. Existing genes were curated for new inheritance patterns where evidence existed. Curations were presented on twice monthly calls, with the HCVD GCEP composed of 29 individuals from 21 institutions across 6 countries. RESULTS: Thirty-one genes were recurated and an additional 5 new potential HCM-associated genes were curated. Among the recurated genes, 17 (55%) genes changed classification: 1 limited and 4 disputed (from no known disease relationship), 9 disputed (from limited), and 3 definitive (from moderate). Among these, 3 (10%) genes had a clinically relevant upgrade, including TNNC1, a 9th sarcomere gene with definitive HCM association. With new evidence, 2 genes were curated for multiple inheritance patterns (TRIM63, disputed for autosomal dominant but moderate for autosomal recessive; ALPK3, strong for autosomal dominant and definitive for recessive). CSRP3 was curated for a semidominant mode of inheritance (definitive). Nine (29%) genes were downgraded to disputed, further discouraging clinical reporting of variants in these genes. Five genes recently reported to cause HCM were curated: RPS6KB1 and RBM20 (limited), KLHL24 and MT-TI (moderate), and FHOD3 (definitive). CONCLUSIONS: We report 29 genes with definitive, strong, or moderate evidence of causation for HCM or isolated left ventricular hypertrophy, including sarcomere, sarcomere-associated, and syndromic conditions.
引用
- Hespe S, Waddell A, Asatryan B, et al. Genes Associated With Hypertrophic Cardiomyopathy: A Reappraisal by the ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel. J Am Coll Cardiol. 2025. PMID: 39971408. doi:10.1016/j.jacc.2024.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。